Re: Xarelto vs Lovenox in immobilized patients (MAGELLAN study)
From the article you posted:
The bold-faced text is corporate-speak for saying that Xarelto is probably dead in this indication. Notably absent in the newswire reports is any statement from JNJ or Bayer that the companies still intend to submit Xarelto for approval in this indication.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.